Combination of pembrolizumab with electrochemotherapy in cutaneous metastases from melanoma [Elektronski vir] : a comparative retrospective study from the InspECT and Slovenian Cancer Registry
Campana, Luca Giovanni, dr. med. ...
Electrochemotherapy (ECT) is an effective locoregional therapy for cutaneous melanoma metastases and has been safely combined with immune checkpoint inhibitors in preliminary experiences. Since ECT ...is known to induce immunogenic cell death, its combination with immune checkpoint inhibitors might be beneficial. In this study, we aimed to investigate the effectiveness of ECT on cutaneous melanoma metastases in combination with pembrolizumab. We undertook a retrospective matched cohort analysis of stage IIIC%IV melanoma patients, included in the International Network for sharing practices of ECT (InspECT) and the Slovenian Cancer Registry. We compared the outcome of patients who received the following treatments: (a) pembrolizumab alone, (b) pembrolizumab plus ECT, and (c) ECT. The groups were matched for age, sex, performance status, and size of skin metastases. The local objective response rate (ORR) was higher in the pembrolizumab-ECT group than in the pembrolizumab group (78% and 39%, p < 0.001). The 1 year local progression-free survival (LPFS) rates were 86% and 51% (p < 0.001), and the 1 year systemic PFS rates were 64% and 39%, respectively (p = 0.034). The 1 year overall survival (OS) rates were 88% and 64%, respectively (p = 0.006). Our results suggest that skin-directed therapy with ECT improves superficial tumor control in melanoma patients treated with pembrolizumab. Interestingly, we observed longer PFS and OS in the pembrolizumab-ECT group than in the pembrolizumab group. These findings warrant prospective confirmation.
Combination of pembrolizumab with electrochemotherapy in cutaneous metastases from melanoma [Elektronski vir] : a comparative retrospective study from the InspECT and Slovenian Cancer Registry
Publication date
2021-08-25
COBISS.SI-ID
74755075
Publication version in repository
Publisher's version
Publication licence
Creative Commons Attribution 4.0 International
Embargo
Immediate publication for public
Project(s) from which the publication was funded
Title
Acronym
Project ID
Funder
Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev
P3-0003-2015
Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
It was not necessary to add the material to the shelf.
Bibliographic material was successfully added on shelf.
Adding bibliographical material on shelf was not successful.
Material is already on the shelf.
Permalink
URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year
Impact factor
Edition
Category
Classification
JCR
SNIP
JCR
SNIP
JCR
SNIP
JCR
SNIP
Select the library membership card:
DRS,
in which the journal is indexed
Database name
Field
Year
Links to authors' personal bibliographies
Links to information on researchers in the SICRIS system
Subject headings in COBISS General List of Subject Headings
Select pickup location
The material from the parent unit is free. If the material is delivered to the pickup location from another unit, the library may charge you for this service.
PDF
https://www.mdpi.com/2072-6694/13/17/4289
